Serial serum c-erbB-2 levels in patients with breast carcinoma

Gena H. Volas, Kim Leitzel, Yoshio Teramoto, Howard Grossberg, Laurence Demers, Allan Lipton

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

BACKGROUND. Recently, the extracellular domain of the c-erbB-2 oncogene product (HER-2/neu) has been reported to be elevated in the serum of one- fourth of patients with metastatic breast carcinoma. The role of serum c- erbB-2 as a tumor marker, however, is still poorly defined. The purpose of this study was to evaluate the utility of serial serum c-erbB-2 levels as a tumor marker in patients with metastatic breast carcinoma. METHODS. c-erbB-2 levels in the sera of patients with breast carcinoma were determined by an enzyme immunoassay that detects the extracellular domain of c-erbB-2. Serum c-erbB-2 levels were evaluated prior to treatment as well as throughout the course of treatment with second-line hormonal therapy employing either megestrol acetate or fadrozole, an experimental aromatase inhibitor. RESULTS. Fifty-eight of 300 patients (19.3%) had elevated pretreatment serum c-erbB-2 levels. Of these 58 patients with elevated pretreatment c-erbB-2, 48 had more than 1 visit which enabled us to quantitate serial c-erbB-2 levels throughout tire course of treatment. Of these 48 patients, 28 (58.3%) had serial c- erbB-2 values that correlated with the clinical course. CONCLUSIONS. Serial serum c-erbB-2 levels did not show a high overall correlation with the clinical course in this group of patients with metastatic breast carcinoma treated with second line hormonal therapy.

Original languageEnglish (US)
Pages (from-to)267-272
Number of pages6
JournalCancer
Volume78
Issue number2
DOIs
StatePublished - Jul 15 1996

Fingerprint

Breast Neoplasms
Serum
Tumor Biomarkers
Fadrozole
Megestrol Acetate
Therapeutics
Aromatase Inhibitors
Oncogene Proteins
Immunoenzyme Techniques

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Volas, Gena H. ; Leitzel, Kim ; Teramoto, Yoshio ; Grossberg, Howard ; Demers, Laurence ; Lipton, Allan. / Serial serum c-erbB-2 levels in patients with breast carcinoma. In: Cancer. 1996 ; Vol. 78, No. 2. pp. 267-272.
@article{30dc346d02d24937bbd4209ee2f0bf77,
title = "Serial serum c-erbB-2 levels in patients with breast carcinoma",
abstract = "BACKGROUND. Recently, the extracellular domain of the c-erbB-2 oncogene product (HER-2/neu) has been reported to be elevated in the serum of one- fourth of patients with metastatic breast carcinoma. The role of serum c- erbB-2 as a tumor marker, however, is still poorly defined. The purpose of this study was to evaluate the utility of serial serum c-erbB-2 levels as a tumor marker in patients with metastatic breast carcinoma. METHODS. c-erbB-2 levels in the sera of patients with breast carcinoma were determined by an enzyme immunoassay that detects the extracellular domain of c-erbB-2. Serum c-erbB-2 levels were evaluated prior to treatment as well as throughout the course of treatment with second-line hormonal therapy employing either megestrol acetate or fadrozole, an experimental aromatase inhibitor. RESULTS. Fifty-eight of 300 patients (19.3{\%}) had elevated pretreatment serum c-erbB-2 levels. Of these 58 patients with elevated pretreatment c-erbB-2, 48 had more than 1 visit which enabled us to quantitate serial c-erbB-2 levels throughout tire course of treatment. Of these 48 patients, 28 (58.3{\%}) had serial c- erbB-2 values that correlated with the clinical course. CONCLUSIONS. Serial serum c-erbB-2 levels did not show a high overall correlation with the clinical course in this group of patients with metastatic breast carcinoma treated with second line hormonal therapy.",
author = "Volas, {Gena H.} and Kim Leitzel and Yoshio Teramoto and Howard Grossberg and Laurence Demers and Allan Lipton",
year = "1996",
month = "7",
day = "15",
doi = "10.1002/(SICI)1097-0142(19960715)78:2<267::AID-CNCR12>3.0.CO;2-U",
language = "English (US)",
volume = "78",
pages = "267--272",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

Serial serum c-erbB-2 levels in patients with breast carcinoma. / Volas, Gena H.; Leitzel, Kim; Teramoto, Yoshio; Grossberg, Howard; Demers, Laurence; Lipton, Allan.

In: Cancer, Vol. 78, No. 2, 15.07.1996, p. 267-272.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serial serum c-erbB-2 levels in patients with breast carcinoma

AU - Volas, Gena H.

AU - Leitzel, Kim

AU - Teramoto, Yoshio

AU - Grossberg, Howard

AU - Demers, Laurence

AU - Lipton, Allan

PY - 1996/7/15

Y1 - 1996/7/15

N2 - BACKGROUND. Recently, the extracellular domain of the c-erbB-2 oncogene product (HER-2/neu) has been reported to be elevated in the serum of one- fourth of patients with metastatic breast carcinoma. The role of serum c- erbB-2 as a tumor marker, however, is still poorly defined. The purpose of this study was to evaluate the utility of serial serum c-erbB-2 levels as a tumor marker in patients with metastatic breast carcinoma. METHODS. c-erbB-2 levels in the sera of patients with breast carcinoma were determined by an enzyme immunoassay that detects the extracellular domain of c-erbB-2. Serum c-erbB-2 levels were evaluated prior to treatment as well as throughout the course of treatment with second-line hormonal therapy employing either megestrol acetate or fadrozole, an experimental aromatase inhibitor. RESULTS. Fifty-eight of 300 patients (19.3%) had elevated pretreatment serum c-erbB-2 levels. Of these 58 patients with elevated pretreatment c-erbB-2, 48 had more than 1 visit which enabled us to quantitate serial c-erbB-2 levels throughout tire course of treatment. Of these 48 patients, 28 (58.3%) had serial c- erbB-2 values that correlated with the clinical course. CONCLUSIONS. Serial serum c-erbB-2 levels did not show a high overall correlation with the clinical course in this group of patients with metastatic breast carcinoma treated with second line hormonal therapy.

AB - BACKGROUND. Recently, the extracellular domain of the c-erbB-2 oncogene product (HER-2/neu) has been reported to be elevated in the serum of one- fourth of patients with metastatic breast carcinoma. The role of serum c- erbB-2 as a tumor marker, however, is still poorly defined. The purpose of this study was to evaluate the utility of serial serum c-erbB-2 levels as a tumor marker in patients with metastatic breast carcinoma. METHODS. c-erbB-2 levels in the sera of patients with breast carcinoma were determined by an enzyme immunoassay that detects the extracellular domain of c-erbB-2. Serum c-erbB-2 levels were evaluated prior to treatment as well as throughout the course of treatment with second-line hormonal therapy employing either megestrol acetate or fadrozole, an experimental aromatase inhibitor. RESULTS. Fifty-eight of 300 patients (19.3%) had elevated pretreatment serum c-erbB-2 levels. Of these 58 patients with elevated pretreatment c-erbB-2, 48 had more than 1 visit which enabled us to quantitate serial c-erbB-2 levels throughout tire course of treatment. Of these 48 patients, 28 (58.3%) had serial c- erbB-2 values that correlated with the clinical course. CONCLUSIONS. Serial serum c-erbB-2 levels did not show a high overall correlation with the clinical course in this group of patients with metastatic breast carcinoma treated with second line hormonal therapy.

UR - http://www.scopus.com/inward/record.url?scp=0030017945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030017945&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19960715)78:2<267::AID-CNCR12>3.0.CO;2-U

DO - 10.1002/(SICI)1097-0142(19960715)78:2<267::AID-CNCR12>3.0.CO;2-U

M3 - Article

C2 - 8674002

AN - SCOPUS:0030017945

VL - 78

SP - 267

EP - 272

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -